3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
2
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
2
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
pertuzumab
3
Vorinostat
3
Specimen Handling
3
Azacitidine
3
venetoclax
2
trametinib
2
ruxolitinib
2
pembrolizumab
2
palbociclib
2
dabrafenib
2
copanlisib
2
aflibercept
2
abiraterone
2
Trastuzumab
2
Sunitinib
2
Sorafenib
2
Oxaliplatin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Immunoglobulin G
2
HhAntag691
2
Fluorouracil
2
Doxorubicin
2
Disulfides
2
Dasatinib
2
Biopsy
2
Bevacizumab
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Inosine Monophosphate
×
Other hematologic neoplasm
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled